Skip to main content
. 2020 Jul 3;34(4):1921–1929. doi: 10.21873/invivo.11989

Table II. Univariable analysis of PFS and OS for nivolumab.

graphic file with name in_vivo-34-1924-i0001.jpg

PFS, Progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor 2; LDH, lactate dehydrogenase; GPS, Glasgow prognostic score; DCBC, disease control by chemotherapy prior to nivolumab